Inadequately Controlled Asthma MedDRA version: 12.0 Level: LLT Classification code 10003553 Term: Asthma
Conditions
Interventions
Product Name: AMG 853
Product Code: AMG 853
Pharmaceutical Form: Coated tablet
INN or Proposed INN: AMG 853
CAS Number: n/a
Current Sponsor code: AMG 853
Other descriptive name: n/a
Concentration unit
Sponsors
Amgen Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Males or females 18 to 65 years of age at the time of screening Percent of predicted FEV1 = 50% and = 80% at screening and baseline visits At least 12% reversibility over pre-bronchodilator FEV1 with SABA inhalation (up to 8 puffs) or nebulized equivalent (up to 2 treatments with 2.5 mg albuterol), demonstrated in the office during screening Inhaled corticosteroid (ICS) = 200 and = 1000 µg/day fluticasone or equivalent. Stable ICS dose for = 30 days before screening and must have used ICS for at least the last 3 consecutive months prior to screening. The ICS dose is expected to remain the same from screening through the end of study. Ongoing asthma symptoms with ACQ score = 1.5 points, at screening and baseline If receiving allergen immunotherapy, a stable dose for > 3 months before screening and anticipated to remain stable for the duration of the study Nonsmoker or ex-smoker with =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Acute asthma exacerbation requiring emergency room treatment or hospitalization within 2 months of screening History of endotracheal intubation for asthma-related exacerbation within 3 years of screening History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma Current diagnosis of sleep apnea with ongoing symptoms or requiring continuous positive airway pressure History of aspirin-sensitive asthma Any uncontrolled, clinically significant systemic disease, (eg, uncontrolled diabetes, liver disease) Any finding on the screening ECG that in the opinion of the investigator requires further cardiovascular evaluation Poorly controlled hypertension defined as resting blood pressure > 150/90 mmHg (assessed on two separate occasions during the screening period) Known malabsorption syndromes (eg, active duodenal ulceration, inflammatory bowel disease; history of small intestine surgery that involved resection or history of gastric bypass) Respiratory infection within 4 weeks of screening visit Any evidence of active infection at screening visit requiring systemic antibiotics Malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if malignancy occurred > 5 years ago, subject is eligible with documentation of disease-free state since treatment) Systemic corticosteroids within 6 weeks before screening visit Received long-acting ß-agonist, theophylline, inhaled anticholinergics, oral ß-2 agonists, or cromolyn therapeutics within 1 week of first run-in visit Leukotriene antagonists within 2 weeks before first run-in visit 5-lipoxygenase inhibitors for asthma (eg, Zyflo®) within 1 week before first run-in visit Previous receipt of AMG 853 Current receipt of any experimental or commercial biologic agent at screening Xolair® within 2 months before screening visit Known positive tuberculin skin test or recent (within 6 months) exposure to a person with active tuberculosis. Subjects with a known positive tuberculin skin test are allowed if: • They have completed treatment with appropriate chemoprophylaxis, or • They have a history of Bacillus Calmette-Guerin vaccination with a negative chest x-ray in the past year, and have no symptoms per the tuberculosis worksheet. Known to have tested positive for hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus Elevated AST/ALT = 1.5 x the upper limit of normal at screening Creatinine clearance < 50 mL/min (based on the Cockroft-Gault formula, calculated by the central laboratory) Bilirubin = 1.5 x the upper limit of normal at screening Laboratory abnormality, which, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results Subject is pregnant or breast feeding Subject is not willing to use highly effective birth control for the duration of the study including the 2-week follow-up period for women (except women at least 2 years post menopausal or surgically sterile) and for up to 10 weeks after the last dose for men (except men whose female partners are at least 2 years post menopausal or surgically sterile). Highly effective methods of birth control are those which result in a low failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine d
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12. ;Secondary Objective: Evaluate the efficacy of AMG 853 as measured by: • Pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1), • AM and PM peak expiratory flow rate (PEFR), • Use of rescue short-acting ß-agonist (SABA), • Daily symptom score (aggregate/night and individual symptoms; and symptom free days), • Asthma quality of life questionnaire (AQLQ). Exploratory Objectives: Evaluate the efficacy of AMG 853 as measured by: • Asthma exacerbations, • Patient global rating of change, • Total serum Immunoglobulin E (IgE), • Exhaled nitric oxide, • Sputum eosinophils (substudy), • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), • Sleep scale from Medical Outcomes Study (Sleep-MOS). Assess the pharmacokinetics of AMG 853. Investigate novel circulating biomarkers in the asthma setting. Safety Objectives: Evaluate the safety of AMG 853 as measured by: • Adverse events, • Changes in electrocardiogram (ECG), • Laboratory profiles, • Vital signs. ;Primary end point(s): Efficacy Endpoint: • Change in ACQ scores from baseline to week 12 | — |
Countries
France, Germany, Italy, Spain, United Kingdom
Outcome results
None listed